{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:13:35Z","timestamp":1769076815192,"version":"3.49.0"},"publisher-location":"Cham","reference-count":151,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032099808","type":"print"},{"value":"9783032099815","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/82_2025_320","type":"book-chapter","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:17:31Z","timestamp":1755011851000},"page":"259-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dengue Vaccines"],"prefix":"10.1007","author":[{"given":"Silvia Beatriz","family":"Boscardin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"320_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fimmu.2014.00263","volume":"5","author":"Y Ambuel","year":"2014","unstructured":"Ambuel Y, Young G, Brewoo JN, Paykel J, Weisgrau KL, Rakasz EG et al (2014) A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates. Front Immunol 5:263. https:\/\/doi.org\/10.3389\/fimmu.2014.00263","journal-title":"Front Immunol"},{"issue":"3","key":"320_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/infdis\/jir279","volume":"204","author":"KB Anderson","year":"2011","unstructured":"Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL et al (2011) Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 204(3):442\u2013450. https:\/\/doi.org\/10.1093\/infdis\/jir279","journal-title":"J Infect Dis"},{"key":"320_CR3","doi-asserted-by":"publisher","unstructured":"Angelo MA, Grifoni A, O\u2019Rourke PH, Sidney J, Paul S, Peters B et al (2017) Human CD4(+) T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J Virol 91(5). https:\/\/doi.org\/10.1128\/JVI.02147-16","DOI":"10.1128\/JVI.02147-16"},{"issue":"3","key":"320_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.vaccine.2005.07.100","volume":"24","author":"D Apt","year":"2006","unstructured":"Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, Skinner C et al (2006) Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24(3):335\u2013344. https:\/\/doi.org\/10.1016\/j.vaccine.2005.07.100","journal-title":"Vaccine"},{"issue":"1","key":"320_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/infdis\/jiq022","volume":"203","author":"C Balas","year":"2011","unstructured":"Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J et al (2011) Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis 203(1):103\u2013108. https:\/\/doi.org\/10.1093\/infdis\/jiq022","journal-title":"J Infect Dis"},{"issue":"2","key":"320_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000790","volume":"6","author":"SJ Balsitis","year":"2010","unstructured":"Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E et al (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6(2):e1000790. https:\/\/doi.org\/10.1371\/journal.ppat.1000790","journal-title":"PLoS Pathog"},{"issue":"304","key":"320_CR7","doi-asserted-by":"publisher","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","volume":"7","author":"PR Beatty","year":"2015","unstructured":"Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E (2015) Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med 7(304):304ra141. https:\/\/doi.org\/10.1126\/scitranslmed.aaa3787","journal-title":"Sci Transl Med"},{"issue":"Suppl 2","key":"320_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s0264-410x(00)00040-2","volume":"18","author":"N Bhamarapravati","year":"2000","unstructured":"Bhamarapravati N, Sutee Y (2000) Live attenuated tetravalent dengue vaccine. Vaccine 18(Suppl 2):44\u201347. https:\/\/doi.org\/10.1016\/s0264-410x(00)00040-2","journal-title":"Vaccine"},{"issue":"8646","key":"320_CR9","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/s0140-6736(89)92471-9","volume":"1","author":"N Bhamarapravati","year":"1989","unstructured":"Bhamarapravati N, Yoksan S (1989) Study of bivalent dengue vaccine in volunteers. Lancet 1(8646):1077. https:\/\/doi.org\/10.1016\/s0140-6736(89)92471-9","journal-title":"Lancet"},{"issue":"2","key":"320_CR10","first-page":"189","volume":"65","author":"N Bhamarapravati","year":"1987","unstructured":"Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A (1987) Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 65(2):189\u2013195","journal-title":"Bull World Health Organ"},{"issue":"7446","key":"320_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al (2013) The global distribution and burden of dengue. Nature 496(7446):504\u2013507. https:\/\/doi.org\/10.1038\/nature12060","journal-title":"Nature"},{"issue":"21","key":"320_CR12","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P et al (2019) Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 381(21):2009\u20132019. https:\/\/doi.org\/10.1056\/NEJMoa1903869","journal-title":"N Engl J Med"},{"issue":"9","key":"320_CR13","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1128\/JVI.79.9.5516-5528.2005","volume":"79","author":"JE Blaney Jr","year":"2005","unstructured":"Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS (2005) Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79(9):5516\u20135528. https:\/\/doi.org\/10.1128\/JVI.79.9.5516-5528.2005","journal-title":"J Virol"},{"issue":"1","key":"320_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/vim.2006.19.10","volume":"19","author":"JE Blaney Jr","year":"2006","unstructured":"Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS (2006) Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 19(1):10\u201332. https:\/\/doi.org\/10.1089\/vim.2006.19.10","journal-title":"Viral Immunol"},{"issue":"4","key":"320_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007721","volume":"15","author":"MB Borges","year":"2019","unstructured":"Borges MB, Marchevsky RS, Carvalho Pereira R, da Silva MY, Almeida Mendes LG, Diniz-Mendes L et al (2019) Detection of post-vaccination enhanced dengue virus infection in macaques: an improved model for early assessment of dengue vaccines. PLoS Pathog 15(4):e1007721. https:\/\/doi.org\/10.1371\/journal.ppat.1007721","journal-title":"PLoS Pathog"},{"issue":"22","key":"320_CR16","doi-asserted-by":"publisher","first-page":"10342","DOI":"10.1073\/pnas.88.22.10342","volume":"88","author":"M Bray","year":"1991","unstructured":"Bray M, Lai CJ (1991) Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci USA 88(22):10342\u201310346. https:\/\/doi.org\/10.1073\/pnas.88.22.10342","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"320_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.vaccine.2011.11.072","volume":"30","author":"JN Brewoo","year":"2012","unstructured":"Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD et al (2012) Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 30(8):1513\u20131520. https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.072","journal-title":"Vaccine"},{"issue":"7","key":"320_CR18","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/jvi.74.7.3011-3019.2000","volume":"74","author":"S Butrapet","year":"2000","unstructured":"Butrapet S, Huang CY, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM (2000) Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5\u2032 noncoding region and nonstructural proteins 1 and 3. J Virol 74(7):3011\u20133019. https:\/\/doi.org\/10.1128\/jvi.74.7.3011-3019.2000","journal-title":"J Virol"},{"issue":"1","key":"320_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2005.06.019","volume":"131","author":"S Butrapet","year":"2006","unstructured":"Butrapet S, Kinney RM, Huang CY (2006) Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J Virol Methods 131(1):1\u20139. https:\/\/doi.org\/10.1016\/j.jviromet.2005.06.019","journal-title":"J Virol Methods"},{"issue":"9951","key":"320_CR20","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN et al (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384(9951):1358\u20131365. https:\/\/doi.org\/10.1016\/S0140-6736(14)61060-6","journal-title":"Lancet"},{"issue":"5","key":"320_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.trstmh.2012.01.013","volume":"106","author":"M Castro","year":"2012","unstructured":"Castro M, Sanchez L, Perez D, Carbonell N, Lefevre P, Vanlerberghe V et al (2012) A community empowerment strategy embedded in a routine dengue vector control programme: a cluster randomised controlled trial. Trans R Soc Trop Med Hyg 106(5):315\u2013321. https:\/\/doi.org\/10.1016\/j.trstmh.2012.01.013","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"320_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","volume":"44","author":"TJ Chambers","year":"1990","unstructured":"Chambers TJ, Hahn CS, Galler R, Rice CM (1990) Flavivirus genome organization, expression, and replication. Ann Rev Microbiol 44:649\u2013688. https:\/\/doi.org\/10.1146\/annurev.mi.44.100190.003245","journal-title":"Ann Rev Microbiol"},{"issue":"4","key":"320_CR23","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","volume":"73","author":"TJ Chambers","year":"1999","unstructured":"Chambers TJ, Nestorowicz A, Mason PW, Rice CM (1999) Yellow fever\/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73(4):3095\u20133101. https:\/\/doi.org\/10.1128\/JVI.73.4.3095-3101.1999","journal-title":"J Virol"},{"issue":"1","key":"320_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4269\/ajtmh.2006.75.1.0750026","volume":"75","author":"P Chanthavanich","year":"2006","unstructured":"Chanthavanich P, Luxemburger C, Sirivichayakul C, Lapphra K, Pengsaa K, Yoksan S et al (2006) Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg 75(1):26\u201328. https:\/\/doi.org\/10.4269\/ajtmh.2006.75.1.0750026","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"320_CR25","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/v3091562","volume":"3","author":"R Chen","year":"2011","unstructured":"Chen R, Vasilakis N (2011) Dengue--quo tu et quo vadis? Viruses 3(9):1562\u20131608. https:\/\/doi.org\/10.3390\/v3091562","journal-title":"Viruses"},{"issue":"8","key":"320_CR26","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1128\/JVI.69.8.5186-5190.1995","volume":"69","author":"W Chen","year":"1995","unstructured":"Chen W, Kawano H, Men R, Clark D, Lai CJ (1995) Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol 69(8):5186\u20135190. https:\/\/doi.org\/10.1128\/JVI.69.8.5186-5190.1995","journal-title":"J Virol"},{"issue":"42","key":"320_CR27","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","volume":"29","author":"BA Coller","year":"2011","unstructured":"Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH (2011) The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29(42):7267\u20137275. https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.021","journal-title":"Vaccine"},{"issue":"Pt 7","key":"320_CR28","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1099\/0022-1317-75-7-1569","volume":"75","author":"C Delenda","year":"1994","unstructured":"Delenda C, Staropoli I, Frenkiel MP, Cabanie L, Deubel V (1994) Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J Gen Virol 75(Pt 7):1569\u20131578. https:\/\/doi.org\/10.1099\/0022-1317-75-7-1569","journal-title":"J Gen Virol"},{"issue":"1","key":"320_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12864-021-07638-7","volume":"22","author":"R Delli Ponti","year":"2021","unstructured":"Delli Ponti R, Mutwil M (2021) Structural landscape of the complete genomes of dengue virus serotypes and other viral hemorrhagic fevers. BMC Genomics 22(1):352. https:\/\/doi.org\/10.1186\/s12864-021-07638-7","journal-title":"BMC Genomics"},{"issue":"2","key":"320_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00436-013-3687-6","volume":"113","author":"CN Dias","year":"2014","unstructured":"Dias CN, Moraes DF (2014) Essential oils and their compounds as Aedes aegypti L. (Diptera: Culicidae) larvicides: review. Parasitol Res 113(2):565\u2013592. https:\/\/doi.org\/10.1007\/s00436-013-3687-6","journal-title":"Parasitol Res"},{"issue":"2","key":"320_CR31","first-page":"133","volume":"22","author":"A Diaz","year":"1988","unstructured":"Diaz A, Kouri G, Guzman MG, Lobaina L, Bravo J, Ruiz A et al (1988) Description of the clinical picture of dengue hemorrhagic fever\/dengue shock syndrome (DHF\/DSS) in adults. Bull Pan Am Health Organ 22(2):133\u2013144","journal-title":"Bull Pan Am Health Organ"},{"issue":"5","key":"320_CR32","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","volume":"98","author":"C Diaz","year":"2018","unstructured":"Diaz C, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG et al (2018) Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico. Am J Trop Med Hyg. 98(5):1435\u20131443. https:\/\/doi.org\/10.4269\/ajtmh.17-0627","journal-title":"Am J Trop Med Hyg."},{"issue":"5","key":"320_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4049\/jimmunol.77.5.352","volume":"77","author":"WR Dorrance","year":"1956","unstructured":"Dorrance WR, Frankel JW, Gordon I, Patterson PR, Schlesinger RW, Winter JW (1956) Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol 77(5):352\u2013364","journal-title":"J Immunol"},{"key":"320_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-3-642-02215-9_10","volume":"338","author":"AP Durbin","year":"2010","unstructured":"Durbin AP, Whitehead SS (2010) Dengue vaccine candidates in development. Curr Top Microbiol Immunol 338:129\u2013143. https:\/\/doi.org\/10.1007\/978-3-642-02215-9_10","journal-title":"Curr Top Microbiol Immunol"},{"issue":"10","key":"320_CR35","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/v3101800","volume":"3","author":"AP Durbin","year":"2011","unstructured":"Durbin AP, Whitehead SS (2011) Next-generation dengue vaccines: novel strategies currently under development. Viruses 3(10):1800\u20131814. https:\/\/doi.org\/10.3390\/v3101800","journal-title":"Viruses"},{"issue":"5","key":"320_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1086\/427780","volume":"191","author":"AP Durbin","year":"2005","unstructured":"Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B et al (2005) rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191(5):710\u2013718. https:\/\/doi.org\/10.1086\/427780","journal-title":"J Infect Dis"},{"issue":"4","key":"320_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4161\/hv.2.4.2944","volume":"2","author":"AP Durbin","year":"2006","unstructured":"Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K et al (2006a) The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2(4):167\u2013173. https:\/\/doi.org\/10.4161\/hv.2.4.2944","journal-title":"Hum Vaccin"},{"issue":"6","key":"320_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4161\/hv.2.6.3494","volume":"2","author":"AP Durbin","year":"2006","unstructured":"Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K et al (2006b) rDEN2\/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2(6):255\u2013260. https:\/\/doi.org\/10.4161\/hv.2.6.3494","journal-title":"Hum Vaccin"},{"issue":"42","key":"320_CR39","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","volume":"29","author":"AP Durbin","year":"2011","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS (2011) Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29(42):7242\u20137250. https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.023","journal-title":"Vaccine"},{"issue":"6","key":"320_CR40","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/infdis\/jis936","volume":"207","author":"AP Durbin","year":"2013","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC et al (2013) A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207(6):957\u2013965. https:\/\/doi.org\/10.1093\/infdis\/jis936","journal-title":"J Infect Dis"},{"issue":"2","key":"320_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.4269\/ajtmh.20-0042","volume":"103","author":"AP Durbin","year":"2020","unstructured":"Durbin AP, Pierce KK, Kirkpatrick BD, Grier P, Sabundayo BP, He H et al (2020) Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: results of a phase-I randomized clinical trial. Am J Trop Med Hyg. 103(2):855\u2013863. https:\/\/doi.org\/10.4269\/ajtmh.20-0042","journal-title":"Am J Trop Med Hyg."},{"key":"320_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ebiom.2016.10.006","volume":"13","author":"A Elong Ngono","year":"2016","unstructured":"Elong Ngono A, Chen HW, Tang WW, Joo Y, King K, Weiskopf D et al (2016) Protective role of cross-reactive CD8 T cells against dengue virus infection. EBioMedicine 13:284\u2013293. https:\/\/doi.org\/10.1016\/j.ebiom.2016.10.006","journal-title":"EBioMedicine"},{"issue":"4","key":"320_CR43","doi-asserted-by":"publisher","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","volume":"92","author":"S Fernandez","year":"2015","unstructured":"Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B et al (2015) An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg. 92(4):698\u2013708. https:\/\/doi.org\/10.4269\/ajtmh.14-0268","journal-title":"Am J Trop Med Hyg."},{"issue":"1","key":"320_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13071-018-2643-9","volume":"11","author":"VH Ferreira-de-Lima","year":"2018","unstructured":"Ferreira-de-Lima VH, Lima-Camara TN (2018) Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. Parasit Vectors 11(1):77. https:\/\/doi.org\/10.1186\/s13071-018-2643-9","journal-title":"Parasit Vectors"},{"issue":"5","key":"320_CR45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.4269\/ajtmh.1991.44.500","volume":"44","author":"BA Fonseca","year":"1991","unstructured":"Fonseca BA, Khoshnood K, Shope RE, Mason PW (1991) Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene. Am J Trop Med Hyg. 44(5):500\u2013508. https:\/\/doi.org\/10.4269\/ajtmh.1991.44.500","journal-title":"Am J Trop Med Hyg."},{"key":"320_CR46","doi-asserted-by":"publisher","unstructured":"Grifoni A, Voic H, Dhanda SK, Kidd CK, Brien JD, Buus S et al (2020) T cell responses induced by attenuated Flavivirus vaccination are specific and show limited cross-reactivity with other Flavivirus species. J Virol 94(10). https:\/\/doi.org\/10.1128\/JVI.00089-20","DOI":"10.1128\/JVI.00089-20"},{"issue":"1","key":"320_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7774\/cevr.2015.4.1.1","volume":"4","author":"T Grunwald","year":"2015","unstructured":"Grunwald T, Ulbert S (2015) Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res 4(1):1\u201310. https:\/\/doi.org\/10.7774\/cevr.2015.4.1.1","journal-title":"Clin Exp Vaccine Res"},{"issue":"12","key":"320_CR48","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1128\/jvi.74.12.5477-5485.2000","volume":"74","author":"F Guirakhoo","year":"2000","unstructured":"Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M et al (2000) Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74(12):5477\u20135485. https:\/\/doi.org\/10.1128\/jvi.74.12.5477-5485.2000","journal-title":"J Virol"},{"issue":"1","key":"320_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1006\/viro.2002.1462","volume":"298","author":"F Guirakhoo","year":"2002","unstructured":"Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R et al (2002) Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298(1):146\u2013159. https:\/\/doi.org\/10.1006\/viro.2002.1462","journal-title":"Virology"},{"issue":"2","key":"320_CR50","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4269\/ajtmh.2009.80.302","volume":"80","author":"B Guy","year":"2009","unstructured":"Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J et al (2009) Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg. 80(2):302\u2013311","journal-title":"Am J Trop Med Hyg."},{"issue":"12","key":"320_CR51","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3390\/v2122649","volume":"2","author":"MG Guzman","year":"2010","unstructured":"Guzman MG, Vazquez S (2010) The complexity of antibody-dependent enhancement of dengue virus infection. Viruses 2(12):2649\u20132662. https:\/\/doi.org\/10.3390\/v2122649","journal-title":"Viruses"},{"issue":"3","key":"320_CR52","first-page":"270","volume":"21","author":"MG Guzman","year":"1987","unstructured":"Guzman MG, Kouri G, Martinez E, Bravo J, Riveron R, Soler M et al (1987) Clinical and serologic study of Cuban children with dengue hemorrhagic fever\/dengue shock syndrome (DHF\/DSS). Bull Pan Am Health Organ 21(3):270\u2013279","journal-title":"Bull Pan Am Health Organ"},{"issue":"12 Suppl","key":"320_CR53","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/nrmicro2460","volume":"8","author":"MG Guzman","year":"2010","unstructured":"Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ et al (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8(12 Suppl):S7\u2013S16. https:\/\/doi.org\/10.1038\/nrmicro2460","journal-title":"Nat Rev Microbiol"},{"issue":"13","key":"320_CR54","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","volume":"373","author":"SR Hadinegoro","year":"2015","unstructured":"Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R et al (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373(13):1195\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa1506223","journal-title":"N Engl J Med"},{"issue":"5","key":"320_CR55","first-page":"350","volume":"42","author":"SB Halstead","year":"1970","unstructured":"Halstead SB (1970) Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42(5):350\u2013362","journal-title":"Yale J Biol Med"},{"key":"320_CR56","doi-asserted-by":"publisher","unstructured":"Halstead SB (2014) Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr 2(6). https:\/\/doi.org\/10.1128\/microbiolspec.AID-0022-2014","DOI":"10.1128\/microbiolspec.AID-0022-2014"},{"issue":"8","key":"320_CR57","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1016\/S2214-109X(24)00226-2","volume":"12","author":"SB Halstead","year":"2024","unstructured":"Halstead SB (2024) Delivering safe dengue vaccines. Lancet Glob Health 12(8):e1229\u2013e1e30. https:\/\/doi.org\/10.1016\/S2214-109X(24)00226-2","journal-title":"Lancet Glob Health"},{"issue":"6 Suppl","key":"320_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690005","volume":"69","author":"SB Halstead","year":"2003","unstructured":"Halstead SB, Marchette NJ (2003) Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg. 69(6 Suppl):5\u201311. https:\/\/doi.org\/10.4269\/ajtmh.2003.69.6_suppl.0690005","journal-title":"Am J Trop Med Hyg."},{"issue":"5596","key":"320_CR59","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/265739a0","volume":"265","author":"SB Halstead","year":"1977","unstructured":"Halstead SB, O\u2019Rourke EJ (1977) Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265(5596):739\u2013741. https:\/\/doi.org\/10.1038\/265739a0","journal-title":"Nature"},{"issue":"5","key":"320_CR60","first-page":"311","volume":"42","author":"SB Halstead","year":"1970","unstructured":"Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42(5):311\u2013328","journal-title":"Yale J Biol Med"},{"issue":"10","key":"320_CR61","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","volume":"10","author":"SB Halstead","year":"2010","unstructured":"Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM (2010) Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 10(10):712\u2013722. https:\/\/doi.org\/10.1016\/S1473-3099(10)70166-3","journal-title":"Lancet Infect Dis"},{"issue":"35","key":"320_CR62","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1016\/j.vaccine.2020.06.079","volume":"38","author":"SB Halstead","year":"2020","unstructured":"Halstead SB, Katzelnick LC, Russell PK, Markoff L, Aguiar M, Dans LR et al (2020) Ethics of a partially effective dengue vaccine: lessons from The Philippines. Vaccine 38(35):5572\u20135576. https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.079","journal-title":"Vaccine"},{"issue":"11","key":"320_CR63","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/nbt.2019","volume":"29","author":"AF Harris","year":"2011","unstructured":"Harris AF, Nimmo D, McKemey AR, Kelly N, Scaife S, Donnelly CA et al (2011) Field performance of engineered male mosquitoes. Nat Biotechnol 29(11):1034\u20131037. https:\/\/doi.org\/10.1038\/nbt.2019","journal-title":"Nat Biotechnol"},{"issue":"16","key":"320_CR64","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1016\/j.vaccine.2006.01.036","volume":"24","author":"L Hermida","year":"2006","unstructured":"Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C et al (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24(16):3165\u20133171. https:\/\/doi.org\/10.1016\/j.vaccine.2006.01.036","journal-title":"Vaccine"},{"issue":"7361","key":"320_CR65","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nature10356","volume":"476","author":"AA Hoffmann","year":"2011","unstructured":"Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F et al (2011) Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 476(7361):454\u2013457. https:\/\/doi.org\/10.1038\/nature10356","journal-title":"Nature"},{"issue":"7","key":"320_CR66","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1128\/jvi.74.7.3020-3028.2000","volume":"74","author":"CY Huang","year":"2000","unstructured":"Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N et al (2000) Chimeric dengue type 2 (vaccine strain PDK-53)\/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74(7):3020\u20133028. https:\/\/doi.org\/10.1128\/jvi.74.7.3020-3028.2000","journal-title":"J Virol"},{"issue":"21","key":"320_CR67","doi-asserted-by":"publisher","first-page":"11436","DOI":"10.1128\/jvi.77.21.11436-11447.2003","volume":"77","author":"CY Huang","year":"2003","unstructured":"Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM (2003) Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77(21):11436\u201311447. https:\/\/doi.org\/10.1128\/jvi.77.21.11436-11447.2003","journal-title":"J Virol"},{"issue":"1","key":"320_CR68","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","volume":"73","author":"AJ Johnson","year":"1999","unstructured":"Johnson AJ, Roehrig JT (1999) New mouse model for dengue virus vaccine testing. J Virol 73(1):783\u2013786. https:\/\/doi.org\/10.1128\/JVI.73.1.783-786.1999","journal-title":"J Virol"},{"issue":"7","key":"320_CR69","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","volume":"20","author":"EG Kallas","year":"2020","unstructured":"Kallas EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T et al (2020) Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect Dis 20(7):839\u2013850. https:\/\/doi.org\/10.1016\/S1473-3099(20)30023-2","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"320_CR70","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","volume":"390","author":"EG Kallas","year":"2024","unstructured":"Kallas EG, Cintra MAT, Moreira JA, Patino EG, Braga PE, Tenorio JCV et al (2024) Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults. N Engl J Med 390(5):397\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2301790","journal-title":"N Engl J Med"},{"issue":"23\u201324","key":"320_CR71","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1016\/s0264-410x(01)00020-2","volume":"19","author":"N Kanesa-thasan","year":"2001","unstructured":"Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A et al (2001) Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19(23\u201324):3179\u20133188. https:\/\/doi.org\/10.1016\/s0264-410x(01)00020-2","journal-title":"Vaccine"},{"issue":"3","key":"320_CR72","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1073\/pnas.1522136113","volume":"113","author":"LC Katzelnick","year":"2016","unstructured":"Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E (2016) Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci USA 113(3):728\u2013733. https:\/\/doi.org\/10.1073\/pnas.1522136113","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2\u20133","key":"320_CR73","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000050045","volume":"44","author":"RM Kinney","year":"2001","unstructured":"Kinney RM, Huang CY (2001) Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44(2\u20133):176\u2013197. https:\/\/doi.org\/10.1159\/000050045","journal-title":"Intervirology"},{"issue":"2","key":"320_CR74","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1006\/viro.1997.8500","volume":"230","author":"RM Kinney","year":"1997","unstructured":"Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N et al (1997) Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230(2):300\u2013308. https:\/\/doi.org\/10.1006\/viro.1997.8500","journal-title":"Virology"},{"issue":"5","key":"320_CR75","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/infdis\/jiv082","volume":"212","author":"BD Kirkpatrick","year":"2015","unstructured":"Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL et al (2015) Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy. Flavivirus-Naive Adults J Infect Dis 212(5):702\u2013710. https:\/\/doi.org\/10.1093\/infdis\/jiv082","journal-title":"Flavivirus-Naive Adults J Infect Dis"},{"issue":"9","key":"320_CR76","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","volume":"24","author":"S Kitchener","year":"2006","unstructured":"Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J et al (2006) Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24(9):1238\u20131241. https:\/\/doi.org\/10.1016\/j.vaccine.2005.09.029","journal-title":"Vaccine"},{"issue":"2","key":"320_CR77","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4269\/ajtmh.1988.38.411","volume":"38","author":"SC Kliks","year":"1988","unstructured":"Kliks SC, Nimmanitya S, Nisalak A, Burke DS (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38(2):411\u2013419. https:\/\/doi.org\/10.4269\/ajtmh.1988.38.411","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"320_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009631","volume":"15","author":"A Kolimenakis","year":"2021","unstructured":"Kolimenakis A, Heinz S, Wilson ML, Winkler V, Yakob L, Michaelakis A et al (2021) The role of urbanisation in the spread of Aedes mosquitoes and the diseases they transmit-a systematic review. PLoS Negl Trop Dis 15(9):e0009631. https:\/\/doi.org\/10.1371\/journal.pntd.0009631","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"320_CR79","first-page":"375","volume":"67","author":"GP Kouri","year":"1989","unstructured":"Kouri GP, Guzman MG, Bravo JR, Triana C (1989) Dengue haemorrhagic fever\/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ 67(4):375\u2013380","journal-title":"Bull World Health Organ"},{"issue":"12","key":"320_CR80","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1073\/pnas.88.12.5139","volume":"88","author":"CJ Lai","year":"1991","unstructured":"Lai CJ, Zhao BT, Hori H, Bray M (1991) Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci USA 88(12):5139\u20135143. https:\/\/doi.org\/10.1073\/pnas.88.12.5139","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"320_CR81","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4269\/ajtmh.19-0738","volume":"103","author":"L Lin","year":"2020","unstructured":"Lin L, Lyke KE, Koren M, Jarman RG, Eckels KH, Lepine E et al (2020) Safety and immunogenicity of an AS03(B)-Adjuvanted inactivated tetravalent dengue virus vaccine administered on varying schedules to healthy U.S. adults: a phase 1\/2 randomized study. Am J Trop Med Hyg. 103(1):132\u2013141. https:\/\/doi.org\/10.4269\/ajtmh.19-0738","journal-title":"Am J Trop Med Hyg."},{"issue":"9","key":"320_CR82","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","volume":"225","author":"E Lopez-Medina","year":"2022","unstructured":"Lopez-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C et al (2022) Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination. J Infect Dis 225(9):1521\u20131532. https:\/\/doi.org\/10.1093\/infdis\/jiaa761","journal-title":"J Infect Dis"},{"issue":"2","key":"320_CR83","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4269\/ajtmh.12-0772","volume":"89","author":"MA Lorono-Pino","year":"2013","unstructured":"Lorono-Pino MA, Garcia-Rejon JE, Machain-Williams C, Gomez-Carro S, Nunez-Ayala G, Najera-Vazquez Mdel R et al (2013) Towards a Casa Segura: a consumer product study of the effect of insecticide-treated curtains on Aedes aegypti and dengue virus infections in the home. Am J Trop Med Hyg 89(2):385\u2013397. https:\/\/doi.org\/10.4269\/ajtmh.12-0772","journal-title":"Am J Trop Med Hyg"},{"issue":"13","key":"320_CR84","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.vaccine.2013.12.040","volume":"32","author":"MP Mammen","year":"2014","unstructured":"Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RC et al (2014) Evaluation of dengue virus strains for human challenge studies. Vaccine 32(13):1488\u20131494. https:\/\/doi.org\/10.1016\/j.vaccine.2013.12.040","journal-title":"Vaccine"},{"issue":"50","key":"320_CR85","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1016\/j.vaccine.2015.09.101","volume":"33","author":"SB Manoff","year":"2015","unstructured":"Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L et al (2015) Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine 33(50):7126\u20137134. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.101","journal-title":"Vaccine"},{"issue":"9","key":"320_CR86","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","volume":"15","author":"SB Manoff","year":"2019","unstructured":"Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D et al (2019) Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a phase I randomized clinical trial in flavivirus-naive adults. Hum Vaccin Immunother 15(9):2195\u20132204. https:\/\/doi.org\/10.1080\/21645515.2018.1546523","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"320_CR87","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4269\/ajtmh.14-0819","volume":"93","author":"LJ Martinez","year":"2015","unstructured":"Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R et al (2015) Safety and immunogenicity of a dengue virus Serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg. 93(3):454\u2013460. https:\/\/doi.org\/10.4269\/ajtmh.14-0819","journal-title":"Am J Trop Med Hyg."},{"issue":"6","key":"320_CR88","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1128\/JVI.70.6.3930-3937.1996","volume":"70","author":"R Men","year":"1996","unstructured":"Men R, Bray M, Clark D, Chanock RM, Lai CJ (1996) Dengue type 4 virus mutants containing deletions in the 3\u2032 noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 70(6):3930\u20133937. https:\/\/doi.org\/10.1128\/JVI.70.6.3930-3937.1996","journal-title":"J Virol"},{"issue":"3","key":"320_CR89","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.tim.2013.12.011","volume":"22","author":"JP Messina","year":"2014","unstructured":"Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA et al (2014) Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol 22(3):138\u2013146. https:\/\/doi.org\/10.1016\/j.tim.2013.12.011","journal-title":"Trends Microbiol"},{"key":"320_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2022.100142","volume":"10","author":"L Mohanty","year":"2022","unstructured":"Mohanty L, Prabhu M, Kumar Mishra A, Purty AJ, Kanungo R, Ghosh G et al (2022) Safety and immunogenicity of a single dose, live-attenuated \u2018tetravalent dengue vaccine\u2019 in healthy Indian adults; a randomized, double-blind, placebo controlled phase I\/II trial. Vaccine X 10:100142. https:\/\/doi.org\/10.1016\/j.jvacx.2022.100142","journal-title":"Vaccine X"},{"issue":"11","key":"320_CR91","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1473-3099(24)00376-1","volume":"24","author":"ML Nogueira","year":"2024","unstructured":"Nogueira ML, Cintra MAT, Moreira JA, Patino EG, Braga PE, Tenorio JCV et al (2024) Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil. Lancet Infect Dis 24(11):1234\u20131244. https:\/\/doi.org\/10.1016\/S1473-3099(24)00376-1","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"320_CR94","doi-asserted-by":"publisher","first-page":"978","DOI":"10.4269\/ajtmh.2011.10-0592","volume":"84","author":"JE Osorio","year":"2011","unstructured":"Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M et al (2011) Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg. 84(6):978\u2013987. https:\/\/doi.org\/10.4269\/ajtmh.2011.10-0592","journal-title":"Am J Trop Med Hyg."},{"issue":"9","key":"320_CR95","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","volume":"14","author":"JE Osorio","year":"2014","unstructured":"Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA et al (2014) Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 14(9):830\u2013838. https:\/\/doi.org\/10.1016\/S1473-3099(14)70811-4","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"320_CR96","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s007050050348","volume":"143","author":"KR Porter","year":"1998","unstructured":"Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG (1998) Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol 143(5):997\u20131003. https:\/\/doi.org\/10.1007\/s007050050348","journal-title":"Arch Virol"},{"key":"320_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2024.105710","volume":"127","author":"M Pourzangiabadi","year":"2025","unstructured":"Pourzangiabadi M, Najafi H, Fallah A, Goudarzi A, Pouladi I (2025) Dengue virus: etiology, epidemiology, pathobiology, and developments in diagnosis and control \u2013 a comprehensive review. Infect Genet Evol 127:105710. https:\/\/doi.org\/10.1016\/j.meegid.2024.105710","journal-title":"Infect Genet Evol"},{"key":"320_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.onehlt.2024.100684","volume":"18","author":"AC Procopio","year":"2024","unstructured":"Procopio AC, Colletta S, Laratta E, Mellace M, Tilocca B, Ceniti C et al (2024) Integrated one health strategies in dengue. One Health 18:100684. https:\/\/doi.org\/10.1016\/j.onehlt.2024.100684","journal-title":"One Health"},{"issue":"2","key":"320_CR99","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1128\/jvi.78.2.1032-1038.2004","volume":"78","author":"KV Pugachev","year":"2004","unstructured":"Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C et al (2004) High fidelity of yellow fever virus RNA polymerase. J Virol 78(2):1032\u20131038. https:\/\/doi.org\/10.1128\/jvi.78.2.1032-1038.2004","journal-title":"J Virol"},{"issue":"6","key":"320_CR100","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","volume":"174","author":"R Putnak","year":"1996","unstructured":"Putnak R, Barvir DA, Burrous JM, Dubois DR, D\u2019Andrea VM, Hoke CH et al (1996a) Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174(6):1176\u20131184. https:\/\/doi.org\/10.1093\/infdis\/174.6.1176","journal-title":"J Infect Dis"},{"issue":"5","key":"320_CR101","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4269\/ajtmh.1996.55.504","volume":"55","author":"R Putnak","year":"1996","unstructured":"Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T et al (1996b) Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg. 55(5):504\u2013510. https:\/\/doi.org\/10.4269\/ajtmh.1996.55.504","journal-title":"Am J Trop Med Hyg."},{"issue":"3","key":"320_CR102","first-page":"143","volume":"40","author":"CG Raut","year":"1996","unstructured":"Raut CG, Deolankar RP, Kolhapure RM, Goverdhan MK (1996) Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus type 2. Acta Virol 40(3):143\u2013146","journal-title":"Acta Virol"},{"issue":"22","key":"320_CR103","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/s0264-410x(99)00570-8","volume":"18","author":"K Raviprakash","year":"2000","unstructured":"Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG et al (2000a) Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18(22):2426\u20132434. https:\/\/doi.org\/10.1016\/s0264-410x(99)00570-8","journal-title":"Vaccine"},{"issue":"Pt 7","key":"320_CR104","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1099\/0022-1317-81-7-1659","volume":"81","author":"K Raviprakash","year":"2000","unstructured":"Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I et al (2000b) Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 81(Pt 7):1659\u20131667. https:\/\/doi.org\/10.1099\/0022-1317-81-7-1659","journal-title":"J Gen Virol"},{"issue":"2","key":"320_CR105","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0042-6822(03)00542-7","volume":"315","author":"K Raviprakash","year":"2003","unstructured":"Raviprakash K, Ewing D, Simmons M, Porter KR, Jones TR, Hayes CG et al (2003) Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315(2):345\u2013352. https:\/\/doi.org\/10.1016\/s0042-6822(03)00542-7","journal-title":"Virology"},{"issue":"1","key":"320_CR106","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.virol.2006.05.005","volume":"353","author":"K Raviprakash","year":"2006","unstructured":"Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G et al (2006) A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 353(1):166\u2013173. https:\/\/doi.org\/10.1016\/j.virol.2006.05.005","journal-title":"Virology"},{"issue":"2","key":"320_CR107","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0042-6822(90)90102-w","volume":"174","author":"R Rico-Hesse","year":"1990","unstructured":"Rico-Hesse R (1990) Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 174(2):479\u2013493. https:\/\/doi.org\/10.1016\/0042-6822(90)90102-w","journal-title":"Virology"},{"key":"320_CR108","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0065-3527(03)59009-1","volume":"59","author":"R Rico-Hesse","year":"2003","unstructured":"Rico-Hesse R (2003) Microevolution and virulence of dengue viruses. Adv Virus Res 59:315\u2013341. https:\/\/doi.org\/10.1016\/s0065-3527(03)59009-1","journal-title":"Adv Virus Res"},{"issue":"35","key":"320_CR109","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","volume":"23","author":"J Robert Putnak","year":"2005","unstructured":"Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I et al (2005) An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23(35):4442\u20134452. https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.042","journal-title":"Vaccine"},{"issue":"3","key":"320_CR110","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","volume":"66","author":"A Sabchareon","year":"2002","unstructured":"Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P et al (2002) Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 66(3):264\u2013272. https:\/\/doi.org\/10.4269\/ajtmh.2002.66.264","journal-title":"Am J Trop Med Hyg."},{"issue":"2","key":"320_CR111","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","volume":"23","author":"A Sabchareon","year":"2004","unstructured":"Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P et al (2004) Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23(2):99\u2013109. https:\/\/doi.org\/10.1097\/01.inf.0000109289.55856.27","journal-title":"Pediatr Infect Dis J"},{"issue":"9853","key":"320_CR112","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","volume":"380","author":"A Sabchareon","year":"2012","unstructured":"Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S et al (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380(9853):1559\u20131567. https:\/\/doi.org\/10.1016\/S0140-6736(12)61428-7","journal-title":"Lancet"},{"issue":"1","key":"320_CR113","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","volume":"1","author":"AB Sabin","year":"1952","unstructured":"Sabin AB (1952) Research on dengue during world war II. Am J Trop Med Hyg. 1(1):30\u201350. https:\/\/doi.org\/10.4269\/ajtmh.1952.1.30","journal-title":"Am J Trop Med Hyg."},{"issue":"2634","key":"320_CR114","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1126\/science.101.2634.640","volume":"101","author":"AB Sabin","year":"1945","unstructured":"Sabin AB, Schlesinger RW (1945) Production of immunity to dengue with virus modified by propagation in mice. Science 101(2634):640\u2013642. https:\/\/doi.org\/10.1126\/science.101.2634.640","journal-title":"Science"},{"issue":"23","key":"320_CR115","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","volume":"24","author":"V Sanchez","year":"2006","unstructured":"Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R et al (2006) Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24(23):4914\u20134926. https:\/\/doi.org\/10.1016\/j.vaccine.2006.03.066","journal-title":"Vaccine"},{"issue":"Pt 3","key":"320_CR116","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1099\/0022-1317-68-3-853","volume":"68","author":"JJ Schlesinger","year":"1987","unstructured":"Schlesinger JJ, Brandriss MW, Walsh EE (1987) Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 68(Pt 3):853\u2013857. https:\/\/doi.org\/10.1099\/0022-1317-68-3-853","journal-title":"J Gen Virol"},{"issue":"20","key":"320_CR117","doi-asserted-by":"publisher","first-page":"10208","DOI":"10.1128\/JVI.00062-06","volume":"80","author":"S Shresta","year":"2006","unstructured":"Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80(20):10208\u201310217. https:\/\/doi.org\/10.1128\/JVI.00062-06","journal-title":"J Virol"},{"issue":"3","key":"320_CR118","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","volume":"78","author":"S Simasathien","year":"2008","unstructured":"Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL et al (2008) Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg. 78(3):426\u2013433","journal-title":"Am J Trop Med Hyg."},{"key":"320_CR119","volume-title":"Experimental studies of dengue","author":"JS Simmons","year":"1931","unstructured":"Simmons JS, Reynolds FHK, John JHS (1931) Experimental studies of dengue"},{"issue":"2","key":"320_CR120","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","volume":"396","author":"M Simmons","year":"2010","unstructured":"Simmons M, Burgess T, Lynch J, Putnak R (2010) Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396(2):280\u2013288. https:\/\/doi.org\/10.1016\/j.virol.2009.10.023","journal-title":"Virology"},{"issue":"15","key":"320_CR121","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMra1110265","volume":"366","author":"CP Simmons","year":"2012","unstructured":"Simmons CP, Farrar JJ, Nguyen V, Wills B (2012) Dengue. N Engl J Med 366(15):1423\u20131432. https:\/\/doi.org\/10.1056\/NEJMra1110265","journal-title":"N Engl J Med"},{"issue":"12","key":"320_CR122","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/infdis\/jit119","volume":"207","author":"SA Smith","year":"2013","unstructured":"Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM et al (2013) Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 207(12):1898\u20131908. https:\/\/doi.org\/10.1093\/infdis\/jit119","journal-title":"J Infect Dis"},{"issue":"4","key":"320_CR123","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T et al (2018) Effect of dengue Serostatus on dengue vaccine safety and efficacy. N Engl J Med 379(4):327\u2013340. https:\/\/doi.org\/10.1056\/NEJMoa1800820","journal-title":"N Engl J Med"},{"issue":"Pt 8","key":"320_CR124","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1099\/0022-1317-78-8-1861","volume":"78","author":"RJ Sugrue","year":"1997","unstructured":"Sugrue RJ, Fu J, Howe J, Chan YC (1997) Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 78(Pt 8):1861\u20131866. https:\/\/doi.org\/10.1099\/0022-1317-78-8-1861","journal-title":"J Gen Virol"},{"issue":"1","key":"320_CR125","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4161\/hv.5.1.6348","volume":"5","author":"W Sun","year":"2009","unstructured":"Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH et al (2009) Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 5(1):33\u201340. https:\/\/doi.org\/10.4161\/hv.5.1.6348","journal-title":"Hum Vaccin"},{"issue":"5","key":"320_CR126","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/infdis\/jis744","volume":"207","author":"W Sun","year":"2013","unstructured":"Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW et al (2013) Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 207(5):700\u2013708. https:\/\/doi.org\/10.1093\/infdis\/jis744","journal-title":"J Infect Dis"},{"issue":"3","key":"320_CR127","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1473-3099(13)70028-8","volume":"13","author":"S Swaminathan","year":"2013","unstructured":"Swaminathan S, Khanna N, Herring B, Mahalingam S (2013) Dengue vaccine efficacy trial: does interference cause failure? Lancet Infect Dis 13(3):191\u2013192. https:\/\/doi.org\/10.1016\/S1473-3099(13)70028-8","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"320_CR128","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/infdis\/jiz109","volume":"220","author":"JA Swanstrom","year":"2019","unstructured":"Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG et al (2019) Beyond neutralizing antibody levels: the epitope specificity of antibodies induced by National Institutes of Health monovalent dengue virus vaccines. J Infect Dis 220(2):219\u2013227. https:\/\/doi.org\/10.1093\/infdis\/jiz109","journal-title":"J Infect Dis"},{"issue":"1","key":"320_CR129","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","volume":"88","author":"SJ Thomas","year":"2013","unstructured":"Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S et al (2013) A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 88(1):73\u201388. https:\/\/doi.org\/10.4269\/ajtmh.2012.12-0361","journal-title":"Am J Trop Med Hyg."},{"key":"320_CR130","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3389\/fimmu.2016.00531","volume":"7","author":"Y Tian","year":"2016","unstructured":"Tian Y, Sette A, Weiskopf D (2016) Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection. Front Immunol 7:531. https:\/\/doi.org\/10.3389\/fimmu.2016.00531","journal-title":"Front Immunol"},{"issue":"2","key":"320_CR131","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","volume":"12","author":"V Tricou","year":"2024","unstructured":"Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C et al (2024) Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet glob. Health 12(2):e257\u2013ee70. https:\/\/doi.org\/10.1016\/S2214-109X(23)00522-3","journal-title":"Health"},{"issue":"5","key":"320_CR132","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4269\/ajtmh.2001.65.414","volume":"65","author":"JM Troyer","year":"2001","unstructured":"Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP et al (2001) A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg. 65(5):414\u2013419. https:\/\/doi.org\/10.4269\/ajtmh.2001.65.414","journal-title":"Am J Trop Med Hyg."},{"issue":"14","key":"320_CR133","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1128\/JVI.00273-15","volume":"89","author":"WY Tsai","year":"2015","unstructured":"Tsai WY, Durbin A, Tsai JJ, Hsieh SC, Whitehead S, Wang WK (2015) Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol 89(14):7348\u20137362. https:\/\/doi.org\/10.1128\/JVI.00273-15","journal-title":"J Virol"},{"issue":"7","key":"320_CR134","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.vaccine.2008.11.106","volume":"27","author":"I Valdes","year":"2009","unstructured":"Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L et al (2009) Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 27(7):995\u20131001. https:\/\/doi.org\/10.1016\/j.vaccine.2008.11.106","journal-title":"Vaccine"},{"issue":"4","key":"320_CR135","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0264-410x(95)00167-y","volume":"14","author":"DW Vaughn","year":"1996","unstructured":"Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM et al (1996) Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14(4):329\u2013336. https:\/\/doi.org\/10.1016\/0264-410x(95)00167-y","journal-title":"Vaccine"},{"issue":"5","key":"320_CR136","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/21645515.2015.1126012","volume":"12","author":"S Velumani","year":"2016","unstructured":"Velumani S, Toh YX, Balasingam S, Archuleta S, Leo YS, Gan VC et al (2016) Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees. Hum Vaccin Immunother 12(5):1265\u20131273. https:\/\/doi.org\/10.1080\/21645515.2015.1126012","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"320_CR137","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C et al (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372(2):113\u2013123. https:\/\/doi.org\/10.1056\/NEJMoa1411037","journal-title":"N Engl J Med"},{"issue":"7361","key":"320_CR138","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature10355","volume":"476","author":"T Walker","year":"2011","unstructured":"Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ et al (2011) The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 476(7361):450\u2013453. https:\/\/doi.org\/10.1038\/nature10355","journal-title":"Nature"},{"issue":"2","key":"320_CR139","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4269\/ajtmh.2011.10-0501","volume":"85","author":"V Watanaveeradej","year":"2011","unstructured":"Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL et al (2011) Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg. 85(2):341\u2013351. https:\/\/doi.org\/10.4269\/ajtmh.2011.10-0501","journal-title":"Am J Trop Med Hyg."},{"issue":"1","key":"320_CR140","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4269\/ajtmh.13-0452","volume":"91","author":"V Watanaveeradej","year":"2014","unstructured":"Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A et al (2014) Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg. 91(1):119\u2013128. https:\/\/doi.org\/10.4269\/ajtmh.13-0452","journal-title":"Am J Trop Med Hyg."},{"issue":"11","key":"320_CR141","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1473-3099(09)70254-3","volume":"9","author":"DP Webster","year":"2009","unstructured":"Webster DP, Farrar J, Rowland-Jones S (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9(11):678\u2013687. https:\/\/doi.org\/10.1016\/S1473-3099(09)70254-3","journal-title":"Lancet Infect Dis"},{"key":"320_CR142","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fimmu.2014.00093","volume":"5","author":"D Weiskopf","year":"2014","unstructured":"Weiskopf D, Sette A (2014) T-cell immunity to infection with dengue virus in humans. Front Immunol 5:93. https:\/\/doi.org\/10.3389\/fimmu.2014.00093","journal-title":"Front Immunol"},{"issue":"11","key":"320_CR143","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/infdis\/jiv289","volume":"212","author":"D Weiskopf","year":"2015","unstructured":"Weiskopf D, Cerpas C, Angelo MA, Bangs DJ, Sidney J, Paul S et al (2015a) Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis 212(11):1743\u20131751. https:\/\/doi.org\/10.1093\/infdis\/jiv289","journal-title":"J Infect Dis"},{"issue":"1","key":"320_CR144","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1128\/JVI.02129-14","volume":"89","author":"D Weiskopf","year":"2015","unstructured":"Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B et al (2015b) The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 89(1):120\u2013128. https:\/\/doi.org\/10.1128\/JVI.02129-14","journal-title":"J Virol"},{"issue":"4","key":"320_CR145","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","volume":"15","author":"SS Whitehead","year":"2016","unstructured":"Whitehead SS (2016) Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? Expert Rev Vaccines 15(4):509\u2013517. https:\/\/doi.org\/10.1586\/14760584.2016.1115727","journal-title":"Expert Rev Vaccines"},{"key":"320_CR146","unstructured":"WHO (2009) Dengue guidelines, for diagnosis, treatment, prevention and control. https:\/\/www.who.int\/publications\/i\/item\/9789241547871. Accessed 4 Mar 2025"},{"key":"320_CR92","unstructured":"WHO (2018) Background paper on dengue vaccines. Prepared by the SAGE working group on dengue vaccines and WHO secretariat. https:\/\/terrance.who.int\/mediacentre\/data\/sage\/SAGE_Docs_Ppt_April2018\/5_session_dengue\/April2018_session5_BGpaper_dengue-vaccines.pdf. Accessed 4 May 2025"},{"key":"320_CR147","unstructured":"WHO (2024a) Disease outbreak news; dengue\u2014global situation. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2024-DON518. Accessed 4 May 2025"},{"key":"320_CR93","unstructured":"WHO (2024b) WHO position paper on dengue vaccines\u2014May 2024. https:\/\/www.who.int\/publications\/i\/item\/who-wer-9918-203-224. Accessed 4 May 2025"},{"issue":"5","key":"320_CR148","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4269\/ajtmh.2009.09-0131","volume":"81","author":"PF Wright","year":"2009","unstructured":"Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE et al (2009) Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4Delta30-4995 in healthy adult volunteers. Am J Trop Med Hyg. 81(5):834\u2013841. https:\/\/doi.org\/10.4269\/ajtmh.2009.09-0131","journal-title":"Am J Trop Med Hyg."},{"key":"320_CR149","first-page":"20","volume":"48","author":"S Yoksan","year":"2017","unstructured":"Yoksan S (2017) Short history of dengue and Mahidol dengue vaccine. South East Asian J Trop Med Pub Health 48:20\u201332","journal-title":"South East Asian J Trop Med Pub Health"},{"issue":"12","key":"320_CR150","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1128\/JVI.61.12.4019-4022.1987","volume":"61","author":"BT Zhao","year":"1987","unstructured":"Zhao BT, Prince G, Horswood R, Eckels K, Summers P, Chanock R et al (1987) Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. J Virol 61(12):4019\u20134022. https:\/\/doi.org\/10.1128\/JVI.61.12.4019-4022.1987","journal-title":"J Virol"},{"issue":"1","key":"320_CR151","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/v4010062","volume":"4","author":"S Zompi","year":"2012","unstructured":"Zompi S, Harris E (2012) Animal models of dengue virus infection. Viruses 4(1):62\u201382. https:\/\/doi.org\/10.3390\/v4010062","journal-title":"Viruses"}],"container-title":["Current Topics in Microbiology and Immunology","Dengue Virus Evolution: From Emergence to a Global Health Crisis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2025_320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:15:57Z","timestamp":1767312957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2025_320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783032099808","9783032099815"],"references-count":151,"URL":"https:\/\/doi.org\/10.1007\/82_2025_320","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"13 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}